ECLIPSE VERTEBRAL SPACER SYSTEM-LUMBAR
Device Facts
| Record ID | K102121 |
|---|---|
| Device Name | ECLIPSE VERTEBRAL SPACER SYSTEM-LUMBAR |
| Applicant | Apollo Spine, Inc. |
| Product Code | OVD · Orthopedic |
| Decision Date | Jan 12, 2011 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
When used as an Intervertebral Body Fusion System: The Eclipse Vertebral Spacer System-Lumbar is indicated for intervertebral body fusion in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine with accompanying radicular symptoms at one disc level from L2-S1. DDD is defined as pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should have completed six weeks of non-operative treatment. The Eclipse Vertebral Spacer System-Lumbar implants are to be used with autogenous bone graft. Supplemental fixation is required. When used as a Vertebral Body Replacement Device: The Eclipse Vertebral Spacer System-Lumbar when used as a vertebral body replacement is intended for use for partial and total replacement of a vertebral body that has been resected or excised due to tumor and/or trauma/fracture. The device is intended for use as a partial vertebral body replacement in the thoracolumbar spine at a single level from T1-L5. These devices are intended to be used with autogenous bone graft. Supplemental fixation is required.
Device Story
Intervertebral body fusion and vertebral body replacement device; maintains intervertebral/vertebral spacing and angulation. Implanted surgically by physicians in clinical settings. Device features superior/inferior surface serrations and positioning pins for placement and radiographic confirmation. Used with autogenous bone graft and required supplemental fixation. Benefits include structural support and stabilization of the spine following disc degeneration, tumor, or trauma.
Clinical Evidence
Bench testing only. No clinical data provided. Testing included static and dynamic compression (ASTM 2077), static and dynamic compression shear (ASTM 2077), subsidence (ASTM 2267), and wear debris analysis.
Technological Characteristics
Materials: PEEK, unalloyed titanium, and Ti6Al4V titanium alloy. Form factor: Spacer with serrated superior/inferior surfaces and positioning pins. Testing standards: ASTM 2077 (compression/shear), ASTM 2267 (subsidence). Non-active, mechanical implant.
Indications for Use
Indicated for skeletally mature patients with lumbar degenerative disc disease (DDD) with radicular symptoms at one level (L2-S1) after 6 weeks of failed non-operative treatment; also indicated for partial/total vertebral body replacement in the thoracolumbar spine (T1-L5) following resection/excision due to tumor or trauma/fracture.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.